Clinical Trial Detail

NCT ID NCT02301130
Title Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kyowa Hakko Kirin Pharma, Inc.
Indications

Advanced Solid Tumor

Therapies

Mogamulizumab

Durvalumab

Tremelimumab

Age Groups: adult

No variant requirements are available.